You are here

Journal of Endovascular Therapy

Journal of Endovascular Therapy

eISSN: 15451550 | ISSN: 15266028 | Current volume: 31 | Current issue: 2 Frequency: Bi-monthly
The Journal of Endovascular Therapy (formerly the Journal of Endovascular Surgery) was established in 1994 as a forum for all physicians, scientists, and allied healthcare professionals who are engaged or interested in endovascular techniques and technology. An official publication of the International Society of Endovascular Specialists (ISEVS), the Journal of Endovascular Therapy publishes peer-reviewed articles of interest to clinicians and researchers in the field of endovascular interventions.

This journal is a member of the Committee on Publication Ethics (COPE).

The Journal’s scope is multidisciplinary, representing all topics related to minimally invasive vascular diagnosis and treatment. Original clinical studies, experimental investigations, systematic reviews, case reports, technical notes, vascular images, editorials, and letters to the editors are published, as well as feature articles related to endovascular interventions, advanced imaging, novel techniques like artificial intelligence and translational research (including basic science) leading to better vascular interventions.

The Journal seeks to support vascular specialists of all disciplines, improve patient care, and promote research and development by publishing peer-reviewed materials related to the field of endovascular therapy.

Alan B. Lumsden, MD Houston, TX, USA
Rodney A. White, MD Torrance, CA, USA
Kak Khee Yeung, MD, PhD, FEBVS Amsterdam, Netherlands
Associate Editors
Jean Bismuth, MD, FACS Houston, TX, USA
Assistant Editors - Artificial Intelligence
Juliette Raffort, MD, PhD Nice, France
Jelmer Wolterink, PhD Utrecht, Netherlands
Assistant Editors
Carlos F. Bechara, MD, DFSVS Maywood, IL, USA
Jan D. Blankensteijn, MD Amsterdam, Netherlands
Jonathan Cardella, MSc, MD, FRCS, FACS New Haven, CT, USA
Allan M. Conway, MBChB (Hons) New York City, NY, USA
Jorg L. de Bruin, MD, PhD, FRCS, FEBVS Rotterdam, Netherlands
Anahita Dua, MD, MS, MBA Boston, MA, USA
Igor Koncar, MD, PhD Belgrade, Serbia
Panos Kougias, MD Houston, TX, USA
Maria Antonella Ruffino, MD, EBIR Turin, Italy
Vittorio Semeraro, MD, PhD Taranto, Italy
Sherene Sharath, PhD, MPH Brooklyn, NY, USA
Joost van der Vorst, MD, PhD Leiden, Netherlands
Clark J. Zeebregts, MD, PhD Groningen, Netherlands
Junior Editors
Bahaa Nasr, MD, PhD Brest, France
Marina Dias Neto, MD, PhD Porto, Portugal
Gergana T. Taneva Madrid, Spain
Editorial Board
Ali F. AbuRahma, MD Charleston, WV, USA
Gary M. Ansel, MD Columbus, OH, USA
Ehrin J. Armstrong, MD, MS St. Helena, CA, USA
Subhash Banerjee, MD Dallas, TX, USA
Frederic Baumann, MD Zurich, Switzerland
Colin D. Bicknell, MD, FRCS London, UK
Gintautas Bieliauskas, MD Copenhagen, Denmark
Giuseppe Biondi Zoccai, MD, Mstat Rome, Italy
Theodosios Bisdas, MD Münster, Germany
Dittmar Böckler, MD, PhD Heidelberg, Germany
Marc Bosiers, MD Dendermonde, Belgium
Johnathan R. Boyle, MD, FRCS Cambridge, UK
Jan S. Brunkwall, MD, PhD Cologne, Germany
Jacques Busquet, MD Paris, France
Victor Costache, MD, PhD Sibiu, Romania
Mike Dake, MD Stanford, CA, USA
Gert De Borst, MD, PhD Utrecht, Netherlands
Gianmarco de Donato Siena, Italy
Jean-Paul P.M. De Vries, MD Groningen, Netherlands
Larry J. Diaz-Sandoval, MD Wyoming, MI, USA
Nicholas Diehm, MD Aarau, Switzerland
Konstantinos Donas, MD Frankfurt, Germany
Zhihui Dong, MD Shanghai, China
Hasan H. Dosluoglu, MD Buffalo, NY, USA
Barry Doyle, PhD Crawley, Australia
Fabrizio Fanelli, MD, EBIR Florence, Italy
C. Alberto Figueroa, PhD Ann Arbor, MI, USA
Robert K. Fisher, MD, FRCS Liverpool, UK
Efstratios Georgakarakos, MD, PhD Alexandroupolis, Greece
Athanasios Giannoukas, MD, PhD Larissa, Greece
Wei Guo, MD Beijing, China
Stephan Haulon, MD Lille, France
Osamu Iida, MD Amagasaki, Japan
William D. Jordan Jr., MD Atlanta, GA, USA
George Joseph, DM Vellore, India
Dimitris Karnabatidis, MD, PhD, EBIR Rion, Greece
Konstantinos Katsanos, MSc, MD, PhD, EBIR London, UK
Osami Kawarada, MD Osaka, Japan
N.N. Khanna New Delhi, India
Tilo Kölbel, MD Hamburg, Germany
Zvonimir Krajcer, MD Houston, TX, USA
John R. Laird, MD St. Helena, CA, USA
Johannes Lammer, MD, EBIR Vienna, Austria
Fabien Lareyre, MD, PhD Antibes, France
Armando C. Lobato, MD Sao Paulo, Brazil
Richard G. McWilliams, MD Liverpool, UK
Marco Midulla, MD, PhD, EBIR Dijon, France
Joseph L. Mills, Sr, MD Houston, TX, USA
Frans Moll, MD, PhD Utrecht, Netherlands
Stefan Müller-Hülsbeck, MD Flensburg, Germany
Erin H. Murphy, MD New York, NY, USA
Gustavo Oderich, MD Rochester, MN, USA
Takao Ohki, MD Tokyo, Japan
Ivo Petrov, MD Sofia, Bulgaria
Ourania Preventza, MD Houston, TX, USA
Zoran Rancic, MD, PhD, FEBVS Zurich, Switzerland
Donald B. Reid, MD, FRCS Edinburgh, United Kingdom
Michel M.P.J. Reijnen, MD, PhD Arnhem, Netherlands
Timothy A. Resch, MD Malmo, Sweden
Carla van Rijswijck, MD, PhD Leiden, Netherlands
Giuseppe Sangiorgi, MD Rome, Italy
Dierk Scheinert, MD Leipzig, Germany
Carlo Setacci, MD Siena, Italy
Nicholas W. Shammas, MD Davenport, IA, USA
Mehdi Shishehbor, DO Cleveland, OH, USA
Chang Shu, MD, PhD Beijing, China
Stavros Spiliopoulos, MD, PhD, EBIR Athens, Greece
Sherif Sultan, MD, FRCS, FEBVS Galway, Ireland
Zhonghua Sun, PhD Perth, Western Australia
Robert A. Taylor, MD Minneapolis, MN, USA
Gunnar Tepe, MD Rosenheim, Germany
Francesco Torella, FRCS Liverpool, UK
Giovanni Torsello, MD Münster, Germany
Ramesh K. Tripathi, FRCS, FRACS Sunshine Coast, Australia
Gilbert R. Upchurch, Jr., MD Charlottesville, VA, USA
Jos C. van den Berg, MD Lugano, Switzerland
Joost A. van Herwaarden, MD, PhD Utrecht, Netherlands
Marc R.H.M. van Sambeek, MD Eindhoven, Netherlands
Ramon Varcoe, FRACS Randwick, Australia
Hence Verhagen, MD Rotterdam, Netherlands
Eric L. G. Verhoeven, MD, PhD Nuremberg, Germany
Lixin Wang, MD, PhD Shanghai, China
Anders Wanhainen, MD, PhD Uppsala, Sweden
Thomas Zeller, MD Bad Krozingen, Germany
Emeritus Editors
Panagiotis E. Balas, MD Athens, Greece
Peter Bell, MD, FRCS Leicester, UK
Thomas J. Fogarty, MD Mountain View, CA, USA
Roger M. Greenhalgh, MD, MChir, FRCS London, UK
Brian R. Hopkinson, MD, FRCS Nottingham, UK
James May, MD, FRACS Sydney, Australia
  • Clarivate Analytics: Science Citation Index Expanded (SCIE)
  • Clarivate Analytics: Science Citation Index Expanded (SCIE)
  • Clarivate Analytics: Science Citation Index Expanded (SCIE)
  • EBSCO: CINAHL Plus with Full Text
  • EMBASE/Excerpta Medica
  • OCLC: Article First
  • OCLC: Electronic Collections Online
  • ProQuest 5000 International
  • ProQuest Central
  • ProQuest Health & Medical Complete
  • ProQuest Medical Library
  • ProQuest Nursing & Allied Health Source
  • PubMed: MEDLINE
  • Research Alert
  • Sociedad Iberoamericana de Informacion Cientifica (SIIC)
  • This Journal is a member of the Committee on Publication Ethics.

    This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).

    Please read the guidelines below then visit the Journal of Endovascular Therapy (JEVT)'s submission site to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned. Remember you can log in to the submission site at any time to check on the progress of your paper through the peer review process.

    Sage Publishing disseminates high-quality research and engaged scholarship globally, and we are committed to diversity and inclusion in publishing. We encourage submissions from a diverse range of authors from across all countries and backgrounds.

    Only manuscripts of sufficient quality that meet the aims and scope of JEVT will be reviewed.

    There are no fees payable to submit or publish in this Journal. Open Access options are available - see section 3.3 below.

    As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you, that you are submitting the work for first publication in the JEVT and that it is not being considered for publication elsewhere and has not already been published elsewhere. Please see our guidelines on prior publication and note that JEVT will consider submissions of papers that have been posted on preprint servers; please alert the Editorial Office when submitting (contact details are at the end of these guidelines) and include the DOI for the preprint in the designated field in the manuscript submission system. Authors should not post an updated version of their paper on the preprint server while it is being peer reviewed for possible publication in the Journal. If the article is accepted for publication, the author may re-use their work according to the Journal's author archiving policy. If your paper is accepted, you must include a link on your preprint to the final version of your paper.

    If you have any questions about publishing with Sage, please visit the Sage Journal Solutions Portal.


    1. What do we publish?
    1.1 Aims & Scope
    1.2 Article types
    1.3 Writing your paper

    2. Editorial policies
    2.1 Peer review policy
    2.2 Authorship
    2.3 Acknowledgements
    2.4 Funding
    2.5 Declaration of conflicting interests
    2.6 Research ethics and patient consent
    2.7 Clinical trials
    2.8 Reporting guidelines
    2.9 Research data

    3. Publishing policies
    3.1 Publication ethics
    3.2 Contributor’s publishing agreement
    3.3 Open access and author archiving

    4. Preparing your manuscript
    4.1 Cover letter
    4.2 Title page file
    4.3 Formatting
    4.4 Artwork, figures, tables and other graphics
    4.5 Identifiable information
    4.6 Supplemental material
    4.7 References and reference style

    5. Submitting your manuscript
    5.1 ORCID
    5.2 Information required for completing your submission
    5.3 Permissions

    6. On acceptance and publication
    6.1 Sage Production
    6.2 Online First publication
    6.3 Access to your published article
    6.4 Promoting your article

    7. Further information
    7.1 Appealing the publication decision


    1. What do we publish?

    1.1 Aims & Scope
    Authors should read the Editorial Policies along with the  Aims & Scope before constructing the manuscript; it contains the Journal’s mission and detailed information about originality, authorship, primacy, research and animal experimentation, patient consent, conflict of interest disclosure, funding, permissions, scientific misconduct, confidentiality, editorial freedom and integrity, peer review, contributor publishing agreement, production, publication, article access and author archiving, and article promotion.  

    1.2 Article types
    Manuscripts considered for publication must be related to peripheral endovascular interventions, written in English, and structured as a clinical or experimental investigation, technical note, editorial, case report, systematic review, vascular image, or letter to the editors.

    • Case Reports may contain descriptions of up to 5 patients; 6 or more cases constitute a series and should be formatted as a Clinical Investigation. They should be one page and include a maximum of 1 figure. Case reports must have a unique and clinically relevant element to qualify for review, as well as at least 6-month imaging follow-up to demonstrate efficacy of a technique or treatment, if appropriate.

    IMPORTANT: We are no longer accepting case reports the whole year but only two times a year in which the top 10 will be selected for publication reviewed by a panel of editors from the editorial board. The two timelines are:

    Between October 1 – December 1
    Between March 1 – May 1

    • A Vascular Image article should be a brief description of the image and its source.

    A Clinical Impact section is required for all submissions (except Editorials and Letters to the Editor) that consist of approximately 100 words, 10 lines maximum. Questions to consider: How will this change clinical practice? What does it mean for the clinicians? What is the innovation behind the study?

    A visual abstract may be submitted with original manuscript submissions. The template to create a visual abstract for JEVT can be downloaded here. Placeholders have been added in the template where authors should add text and graphics/icons as applicable for their content.

    Registered Reports, Pre-Data or Post-Data:  There are two types of Registered Reports:  

    • Registered Reports – Pre-Data, i.e., before any data have been gathered
    • Registered Reports – Post-Data, i.e., before already existing data have been examined and analysed.   

    These submissions are reviewed in two stages. In Stage 1, a study proposal is considered for publication prior to data collection and/or analysis. Stage 1 submissions should include a complete Introduction, Methods, and Proposed Analyses. High-quality proposals will be accepted in principle before data collection and/or data analysis commences. Once the study is completed, the author will finish the article including Results and Discussion sections (Stage 2). Publication of the Stage 2 submission is guaranteed as long as the approved Stage 1 protocol is followed and the conclusions are appropriate. Full details can be found here. The Journal’s manuscript requirements should be adhered to for the stage 2 submission.

    1.3 Writing your paper

    The Sage Author Gateway has some general advice and on how to get published, plus links to further resources. Sage Author Services also offers authors a variety of ways to improve and enhance their article including English language editing, plagiarism detection, and video abstract and infographic preparation.

    • For example, the title, keywords, and abstract are vital to ensuring discoverability in search engines. For information and guidance on how best to title an article, write an abstract, or select keywords, consult How to Help Readers Find Your Article Online.

    Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the Journal’s specifications should consider using Sage Language Services. Visit Sage Language Services on our Journal Author Gateway for further information.


    2. Editorial policies

    2.1 Peer review policy
    JEVT uses double-anonymized review, so no information that could identify the source of the submission (eg, author or institution names) can appear in the manuscript file.

    Sage does not permit the use of author-suggested (recommended) reviewers at any stage of the submission process, be that through the web-based submission system or other communication.

    Reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Our policy is that reviewers should not be assigned to a paper if:

    • The reviewer is based at the same institution as any of the co-authors.

    • The reviewer is based at the funding body of the paper.

    • The author has recommended the reviewer.

    • The reviewer has provided a personal (e.g. Gmail/Yahoo/Hotmail) email account and an institutional email account cannot be found after performing a basic Google search (name, department and institution).

    JEVT is committed to delivering high quality, fast peer-review for your paper, and as such has partnered with Publons. Publons is a third-party service that seeks to track, verify and give credit for peer review. Reviewers for the journal can opt in to Publons in order to claim their reviews or have them automatically verified and added to their reviewer profile. Reviewers claiming credit for their review will be associated with the relevant journal, but the article name, reviewer’s decision and the content of their review is not published on the site. For more information visit the Publons website.

    The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the Journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor/Board member will have no involvement in the decision-making process.

    2.2 Authorship
    Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.

    The list of authors should include all those who can legitimately claim authorship. This is all those who:

    1. Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,

    2. Drafted the article or revised it critically for important intellectual content,

    3. Approved the version to be published,

    4. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.

    Authors should meet the conditions of all of the points above. When a large, multicenter group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.

    Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.

    Please note that AI chatbots, for example ChatGPT, should not be listed as authors. For more information see the policy on Use of ChatGPT and generative AI tools.

    2.3 Acknowledgements
    All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.

    Please supply any personal acknowledgements separately to the main text to facilitate anonymous peer review.

    Per ICMJE recommendations, it is best practice to obtain consent from non-author contributors who you are acknowledging in your paper.                                                       

    2.3.1 Third party submissions
    Where an individual who is not listed as an author submits a manuscript on behalf of the author(s), a statement must be included in the Acknowledgements section of the manuscript and in the accompanying cover letter. The statements must:

    • Disclose this type of editorial assistance – including the individual’s name, company and level of input
    • Identify any entities that paid for this assistance
    • Confirm that the listed authors have authorized the submission of their manuscript via third party and approved any statements or declarations, e.g. conflicting interests, funding, etc.

    Where appropriate, Sage reserves the right to deny consideration to manuscripts submitted by a third party rather than by the authors themselves.

    2.3.2 Writing assistance
    Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. It is not necessary to disclose use of language polishing services.

    2.4 Funding
    JEVT requires all authors to acknowledge their funding in a consistent fashion under a separate heading.  Please visit the Funding Acknowledgements page on the Sage Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. 

    2.5 Declaration of conflicting interests
    It is the policy of JEVT to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.
    Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’. For guidance on conflict of interest statements, please see the ICMJE recommendations here.

    2.6 Research ethics and patient consent
    Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.

    Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant ethics committee or institutional review board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.

    For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.

    Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative. Please do not submit the patient’s actual written informed consent with your article, as this in itself breaches the patient’s confidentiality. The Journal requests that you confirm to us, in writing, that you have obtained written informed consent but the written consent itself should be held by the authors/investigators themselves, for example in a patient’s hospital record. The confirmatory letter may be uploaded with your submission as a separate file.

    Please also refer to the ICMJE Recommendations for the Protection of Research Participants.

    2.7 Clinical trials
    JEVT conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.

    2.8 Reporting guidelines
    The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.

    Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.

    2.9 Research data
    The Journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages.

    Subject to appropriate ethical and legal considerations, authors are encouraged to:

    • Share your research data in a relevant public data repository

    • Include a data availability statement linking to your data. If it is not possible to share your data, use the statement to confirm why it cannot be shared.

    • Cite this data in your research


    3. Publishing policies

    3.1 Publication ethics
    Sage is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the Sage Author Gateway.

    3.1.1 Plagiarism
    JEVT and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the Journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.

    3.1.2 Prior publication
    If material has been previously published it is not generally acceptable for publication in a Sage journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the Sage Author Gateway or if in doubt, contact the journal’s editorial office at

    3.2 Contributor’s publishing agreement      
    Before publication, Sage requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. Sage’s Journal Contributor’s Publishing Agreement is an exclusive license agreement which means that the author retains copyright in the work but grants Sage the sole and exclusive right and license to publish for the full legal term of copyright. Exceptions may exist where an assignment of copyright is required or preferred by a proprietor other than Sage. In this case copyright in the work will be assigned from the author to the society. For more information, please visit the Sage Author Gateway.

    3.3 Open access and author archiving
    JEVT offers optional open access publishing via the Sage Choice programme and Open Access agreements, where authors can publish open access either discounted or free of charge depending on the agreement with Sage. Find out if your institution is participating by visiting Open Access Agreements at Sage. For more information on Open Access publishing options at Sage please visit Sage Open Access. For information on funding body compliance, and depositing your article in repositories, please visit Sage’s Author Archiving and Re-Use Guidelines and Publishing Policies.


    4. Preparing your manuscript for submission

    4.1 Cover Letter
    Manuscripts (except correspondence) must be accompanied by a cover letter signed by the corresponding author on behalf of all authors stating (1) there has been no duplicate publication or submission of any part of the work; (2) all authors have read and approved the manuscript; and (3) there is no financial arrangement or other relationship that could be construed as a conflict of interest. If a potential conflict exists, its nature should be stated in the letter and on the title page for each author involved (see Editorial Policies: Conflict of Interest Disclosure).

    4.2 Title Page File

    • Construct a title that does not exceed 50 words and does not contain acronyms other than those referring to clinical trials.

    • List first and last names, highest academic degree(s), affiliations, and email addresses for all authors.

    • Give the total word count.

    • Acknowledge all sources of financial support (grants, fellow-ships, equipment, or remuneration of any kind) and any relationships that may be considered a conflict of interest (ie, employment, stock-holdings, retainers, paid or unpaid consultancies, patents or patent licensing arrangements, or honoraria) that may pertain to the manuscript (see Editorial Policies: Conflict of Interest Disclosure).

    • Give details of any prior presentation, including meeting name, location, and date.

    • List acknowledgments, any shared first authorship, and other author notes.

    • Give the name, mailing address, and email address of the corresponding author.

    4.3 Formatting

    • The preferred format for your manuscript is Word. LaTeX files are also accepted. A LaTex template is available on the Manuscript Submission Guidelines page of our Author Gateway.

    • There is no word limit for manuscripts, but abstract length is restricted for some types of articles (see Section 4.3.1).

    • Text material must be submitted as a single Word document (not a PDF) named the “Main document.” Type the title at the top of the first page followed by the abstract and keywords, text, references, appendix (if applicable), and figure legends (see Section 4.4.3). Tables, figures, movies, and supplementary material are delivered as separate files [see Section 4.6].

    • Type section heads in bold (initial capital) letters at the left margin (do not center); subheads appear in italics (initial capital) at the left margin. Third-level heads are in italicized type (first word capitalized) and indented to run in with the text.

    Section Head

    Second-Level Head

                    Third-Level Head

    • Do not embed any elements in the text, including fonts, links, footnotes in hidden fields, field codes, bookmarks, comments, passwords, objects, worksheets, databases, artwork, or slides (eg, PowerPoint).

    • Use the formatting function for bold, italic, and sub/superscripts. Symbols, foreign letters, and short (1-line) mathematical formulas may be inline in the text (see Section 4.3.2).

    • Because the manuscripts will undergo anonymized review, no author or institution name should appear in the text or header/footer.

    4.3.1 Abstract

    • Give a substantive summary of an original article in 350 words or less, separating the abstract according to Purpose, Materials and Methods, Results, and Conclusion. For case reports, the abstract should be no longer than 200 words and divided into Purpose, Case Report, and Conclusion. Technical notes also have a maximum 200-word abstract divided into Purpose, Technique, and Conclusion. Abstracts for review articles may be unstructured.

    • Provide up to 10 keywords.

    4.3.2 Text

    • Organize the text for clinical or experimental investigations into sections entitled Introduction, Materials and Methods, Results, Discussion, and Conclusion. Case reports require only Introduction, Case Report, Discussion, and Conclusion. Likewise, technical notes should be sectioned as Introduction, Technique, Discussion, and Conclu-sion. Editorials, vascular images, and reviews may be structured as appropriate for the material.

    • Avoid naming any institution(s) in the work or otherwise identifying the author(s).

    • Use SI measurements; generic drug names should be used.

    • Define abbreviations and acronyms when they first appear in the text; do not list them at the beginning of the manuscript file.

    • Give registration information for clinical trials and systematic reviews in Materials and Methods.

    • Identify tables and figures using Arabic numerals in parentheses (eg, Figure 1).

    • Place equations appearing in the text on their own line and number serially toward the right margin:

    v1A1 = v2A2              (1)

    • Short expressions without a number can be inline with the text. Complex equations should be prepared with appropriate software and inserted to flow with the text.

    • P values should be formatted p=0.XXX and limited to 3 digits.

    • Interquartile ranges should be presented as Q3 – Q1 (eg, 15.4) or Q1, Q3 (eg, 12, 27).

    4.3.3 Survival Analyses

    • For survival (time-to-event) analysis, the Kaplan-Meier (KM) method is preferred and should follow the intent-to-treat principle for the at-risk population. The life table method is appropriate for only very large populations (eg, epidemiological studies). The minimum group size for survival analysis using the KM method is 20 subjects at the start of the observation period. All datasets should be terminated at the time point when there are <10 patients remaining in any group.

    • All Kaplan-Meier graphs require (1) the x axis in months or years, (2) the at-risk/interval patient numbers per group from time zero (intent-to-treat), (3) the number of events per interval, and (4) the standard errors (SE) of the survival estimates (not the mean) per interval per group. SEs are calculated using the Greenwood formula and are reported as percentages. The at-risk numbers, events, and SEs can be given in a table within or below the plot area. Alternatively, the SE can be reported as a statement in the figure legend as to the time point at which the SE exceeds 10% for each group.

    • KM estimates are valid only so long as the SE remains <10% AND the at-risk numbers in all groups are a minimum of 10. Report the valid KM estimates in the text with the 95%confidence intervals (CIs), not the SEs. When configuring the graph, do not plot the 95% CIs.

    • Deliver each graph as a 600-dpi TIF file; do not upload images in a Word document, PDF, or PowerPoint file.

    4.4 Artwork, figures, tables and other graphics

    4.4.1. Figures and other graphics

    • Number using Arabic numerals any pictures, charts, graphs, or line art sequentially as figures.

    • Use color judiciously in pictures and graphics. Figures will be printed in grayscale unless color charges are paid. The fees for color are $800 for the first figure and $200 for each additional color figure for print/online display.

    • Figures supplied in color will appear in color online at no charge regardless of whether or not these illustrations are reproduced in color in the printed version. Please type “Print color requested” at the end of the legend of any figure that requires color reproduction in print. Sage will send information regarding the color fee at the proof stage after an article has been accepted.

    • Format charts and graphs using markers and line styles to differentiate the data series unless the figure is to be printed in color (fee applicable).

    • Add arrows and symbols using functions supplied with the image editing software.

    • Do not import images into the text document but transmit each image file separately.

    • Supply all figures in a digital format of suitable quality for printing: TIF for pictures or EPS for graphs and line drawings (to preserve quality when enlarged/zoomed). Image resolution should be at least 400 ppi for color or grayscale images and 600 ppi (preferably higher) for black and white line drawings or graphs. Image size at these resolutions should be no less than 3 inches (7.6 cm) wide for vertical images and 5 inches (12.7 cm) wide for horizontally-oriented figures. Use a lossless compression algorithm (eg, LZW) that does not degrade the resolution.

    • Convert PowerPoint slides to individual TIF files for upload. Do not upload images in a Word document or PDF.

    • Upload each image file and enter the legend in the caption box.

    4.4.2 Movie Files

    • Submit video clips (up to 50 Mb each) in AVI, MP4, MPEG, or MOV formats. Legends must be provided along with the figure legends, and the callout location of each movie must appear in the text.

    • Upload a movie as an “Image” with its legend in the caption box.

    4.4.3 Legends

    • Type all figure and movie legends on a separate page of the manuscript file, explaining abbreviations and symbols used in the figure. Previously published figures must be acknowledged and accompanied by written permission from the publisher to reproduce the material if it is copyrighted.

    • Do not use Word’s caption function for figure legends or include the actual figures in the manuscript file.

    4.4.4 Table Files

    • Use tables to supplement the text, not duplicate it.

    • Make separate Word files for each table, number them sequentially using Arabic numerals, and give a title at the top of the page. Do not insert tables in the text or create/save tables as an image.

    • Format tables using the table formatting function in Word; artistic formatting (shading, color) should not be used.

    • Define any abbreviations as the first footnote under the table; list the abbreviations alphabetically.

    • Use footnotes for explanatory material, labeling each with a superscript lower case letter (a-z) in alphabetical order.

    • Explain the format(s) for the data in the table, eg, “Continuous data are presented as the means ± standard deviation; categorical data are given as the counts (percentage).”

    For more guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit Sage’s Manuscript Submission Guidelines.

    4.5 Identifiable information
    Where a journal uses double-anonymized peer review, authors are required to submit:

    1. A version of the manuscript which has had any information that compromises the anonymity of the author(s) removed or anonymized. This version will be sent to the peer reviewers.

    2. A separate title page which includes any removed or anonymized material. This will not be sent to the peer reviewers.

    See for detailed guidance on making an anonymous submission.

    4.6 Supplemental material
    This Journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc.) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplemental files.

    Follow the formatting instructions in Section 4.2 for any supplementary figures, tables, reference lists, appendices, etc. Each item (eg, table, figure) should be named Supplementary Table 1, Supplementary Figure 1, etc, and uploaded as a “supplementary file.” Material for online only display will appear exactly as submitted; it will not be typeset.

    4.7 References and reference style
    Limit to 15 the number of references for a case report, technical note, or vascular image. Letters may have no more than 10 references. Other article types have no limitations on references.

    Follow the guidelines for references in the AMA Manual of Style (11th ed., 2020). Select the “AMA” format for citations copied from PubMed. Number references in the order of appearance in the text. Identify references in the text, tables, and legends with superscript Arabic numerals.


    5. Submitting your manuscript

    JEVT is hosted on Sage Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit to login and submit your article online.

    IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.

    5.1 ORCID
    As part of our commitment to ensuring an ethical, transparent and fair peer review process Sage is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a unique and persistent digital identifier that distinguishes researchers from every other researcher, even those who share the same name, and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities, ensuring that their work is recognized.

    The collection of ORCID IDs from corresponding authors is required during the submission process for the Journal. If you already have an ORCID ID you will be asked to associate that to your submission during the online submission process. We also strongly encourage all co-authors to link their ORCID ID to their accounts in our online peer review platforms. It takes seconds to do: click the link when prompted, sign into your ORCID account and our systems are automatically updated. Your ORCID ID will become part of your accepted publication’s metadata, making your work attributable to you and only you. Your ORCID ID is published with your article so that fellow researchers reading your work can link to your ORCID profile and from there link to your other publications.

    If you do not already have an ORCID ID please follow this link to create one or visit our ORCID homepage to learn more.

    5.2 Information required for completing your submission
    You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. The affiliation listed in the manuscript should be the institution where the research was conducted. If an author has moved to a new institution since completing the research, the new affiliation can be included in a manuscript note at the end of the paper. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).

    5.3 Permissions
    Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the Sage Author Gateway.


    6. On acceptance and publication           

    Accepted manuscripts will be prepared for publication after the corresponding author has signed the Sage Journal Contributor’s Publishing Agreement. JEVT reserves the right to edit accepted manuscripts to comply with the journal’s format, to correct grammatical faults and remove redundancies, and to improve readability and organization without altering the meaning. The corresponding author will receive a link to the Sage Edit website to review the proofs, which must be completed within 2 days. After that, the corrected proof is sent to Online First for publishing while awaiting publication in print.

    6.1 Sage Production
    Your Sage Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be made available to the corresponding author via our editing portal Sage Edit or by email, and corrections should be made directly or notified to us promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate.

    6.2 Online First publication
    Online First allows final articles (completed and approved articles awaiting assignment to a future issue) to be published online prior to their inclusion in a journal issue, which significantly reduces the lead time between submission and publication. Visit the Sage Journals help page for more details, including how to cite Online First articles.

    6.3 Access to your published article
    Sage provides authors with online access to their final article.

    6.4 Promoting your article
    Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The Sage Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice.


    7. Further information

    Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the JEVT editorial office as follows:

    7.1 Appealing the publication decision
    Editors have very broad discretion in determining whether an article is an appropriate fit for their journal. Many manuscripts are declined with a very general statement of the rejection decision. These decisions are not eligible for formal appeal unless the author believes the decision to reject the manuscript was based on an error in the review of the article, in which case the author may appeal the decision by providing the Editor with a detailed written description of the error they believe occurred.

    If an author believes the decision regarding their manuscript was affected by a publication ethics breach, the author may contact the publisher with a detailed written description of their concern, and information supporting the concern, at

    Individual Subscription, E-access

    Individual Subscription, Combined (Print & E-access)

    Institutional Subscription, E-access

    Institutional Backfile Purchase, E-access (Content through 1998)

    Institutional Subscription & Backfile Lease, E-access Plus Backfile (All Online Content)

    Institutional Subscription, Print Only

    Institutional Subscription, Combined (Print & E-access)

    Institutional Subscription & Backfile Lease, Combined Plus Backfile (Current Volume Print & All Online Content)

    Individual, Single Print Issue

    Institutional, Single Print Issue